Evidence map›Paper›PMID 28231800›Full record

ArticleLipids in health and disease2017

Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.

Jef Verbeek, Pieter Spincemaille, Ilse Vanhorebeek, Greet Van den Berghe, Ingrid Vander Elst, Petra Windmolders, Jos van Pelt, Schalk van der Merwe, Pierre Bedossa, Frederik Nevens and 3 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Lipids in health and disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Jef VerbeekDepartment of Hepatology, University Hospitals KU Leuven, Leuven, Belgium. jef.verbeek@mumc.nl.ORCID http://orcid.org/0000-0002-1549-8003
Pieter SpincemailleDepartment of Laboratory Medicine, University Hospitals KU Leuven, Leuven, Belgium.
Ilse VanhorebeekClinical Department and Laboratory of Intensive Care Medicine, Division Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Greet Van den BergheClinical Department and Laboratory of Intensive Care Medicine, Division Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Ingrid Vander ElstDepartment of Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
Petra WindmoldersDepartment of Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
Jos van PeltDepartment of Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
Schalk van der MerweDepartment of Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
Pierre BedossaDepartment of Pathology, Hopital Beaujon, Clichy, France.
Frederik NevensDepartment of Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
Bruno CammueCentre of Microbial and Plant Genetics (CMPG), KU Leuven, Leuven, Belgium.
Karin ThevissenCentre of Microbial and Plant Genetics (CMPG), KU Leuven, Leuven, Belgium.
David CassimanDepartment of Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
KU Leuven · BEHôpital Beaujon · FRMaastricht University Medical Centre · NLVlaams Instituut voor Biotechnologie · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDietary intervention is the cornerstone of non-alcoholic steatohepatitis (NASH) treatment. However, histological evidence of its efficacy is limited and its impact on hepatic pathways involved in NASH is underreported. The efficacy of the angiotensin receptor type 1 blocker losartan is controversial because of varying results in a few animal and human studies. We evaluated the effect of dietary intervention versus losartan on NASH and associated systemic metabolic features in a representative mouse model.

methodsMale C57BL/6 J mice with high fat-high sucrose diet (HF-HSD) induced NASH, obesity, insulin resistance and hypercholesterolemia were subjected to dietary intervention (switch from HF-HSD to normal chow diet (NCD)) (n = 9), continuation HF-HSD together with losartan (30 mg/kg/day) (n = 9) or continuation HF-HSD only (n = 9) for 8 weeks. 9 mice received NCD during the entire experiment (20 weeks). We assessed the systemic metabolic effects and performed a detailed hepatic histological and molecular profiling. A P-value of < 0.05, using the group with continuation of HF-HSD only as control, was considered as statistically significant.

resultsDietary intervention normalized obesity, insulin resistance, and hypercholesterolemia (for all P < 0.001), and remarkably, completely reversed all histological features of pre-existent NASH (for all P < 0.001), including fibrosis measured by quantification of collagen proportional area (P < 0.01). At the hepatic molecular level, dietary intervention targeted fibrogenesis with a normalization of collagen type I alpha 1, transforming growth factor β1, tissue inhibitor of metalloproteinase 1 mRNA levels (for all P < 0.01), lipid metabolism with a normalization of fatty acid translocase/CD36, fatty acid transport protein 5, fatty acid synthase mRNA levels (P < 0.05) and markers related to mitochondrial function with a normalization of hepatic ATP content (P < 0.05) together with sirtuin1 and uncoupling protein 2 mRNA levels (for both P < 0.001). Dietary intervention abolished p62 accumulation (P < 0.01), suggesting a restoration of autophagic flux. Losartan did not significantly affect obesity, insulin resistance, hypercholesterolemia or any histological NASH feature.

conclusionsDietary intervention, and not losartan, completely restores the metabolic phenotype in a representative mouse model with pre-existent NASH, obesity, insulin resistance and hypercholesterolemia.

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsCD36 AntigensCollagen Type I, alpha 1 ChainDrug Evaluation, PreclinicalGene ExpressionInsulin ResistanceLosartanMaleMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseObesitySterol Regulatory Element Binding Protein 1Angiotensin II Type 1 Receptor BlockersCD36 AntigensCOL1A1 protein, humanCollagen Type I, alpha 1 ChainLosartanSterol Regulatory Element Binding Protein 1AngiotensinDietLosartanNASHtreatment

Identifiers

PMID28231800
PMCPMC5324232
OpenAlexW2591537762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.